Table 1.
Prediction of HLA-A*0201 peptide from 40 cases B-ALL patients
| number | Sequence | subfamily | position | SYFPEITHI score | BIMAS t1/2(min) |
|---|---|---|---|---|---|
| 1 | QLVQSGAEV | IgHV1/5 | FR1(3–11) | 24 | 69.552 |
| 2 | TLVKPTQTL | IgHV2 | FR1(10–18) | 25 | 21.362 |
| 3 | SLSTSGVGV | IgHV2 | FR1/CDR1(28–36) | 25 | 68.552 |
| 4 | SLYLQMNSL | IgHV3 | FR3(78–86) | 26 | 157.227 |
| 5 | TLYLQMNSL | IgHV3 | FR3(78–86) | 24 | 157.227 |
| 6 | QLQESGPGL | IgHV4 | FR1(3–11) | 24 | 87.586 |
| 7 | QLQQWGAGL | IgHV4 | FR1(3–11) | 23 | 21.362 |
| 8 | GLLKPSETL | IgHV4 | FR1(10–18) | 26 | 38.730 |
| 9 | GLVKPSETL | IgHV4 | FR1(10–18) | 24 | 10.468 |
| 10 | QLQQSGPGL | IgHV6 | FR1(3–11) | 22 | 21.362 |
| 11 | GLVKPSQTL | IgHV6 | FR1(10–18) | 24 | 21.362 |
| 12 | VLLWFRELL | / | CDR3(106–114) | 24 | 25.196 |
Shown are the number, sequence (single-letter abbreviations for amino acids), position, subfamily, calculated score of predicted BIMAS and SYFPEITHI prediction programs. We ranked one or two top score peptides in each IgHV subfamily
FR framework region, CDR complementary-determining region, ND not determined, B-ALL acute B- lymphoblastic leukemia